🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Cancer turns your world upside down. 💝At EORTC, we understand the challenges cancer patients face after diagnosis. 👬This #WorldCancerDay, let’s stand together and ensure that no cancer patient is left behind. Learn more: worldcancerday.org/take-action/up… #CancerResearch #Oncology

On #WorldCancerDay, we had the pleasure of hosting a stimulating debate in collaboration with Breast International Group to mark the premiere of L'Amazone, a movie about #BreastCancer. 🎥 Watch our interview with the Co-Director Émilie Maréchal & Dr Michail ignatiadis👇 #CancerResearch #Oncology

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer oncodaily.com/url/239731 Giampaolo Bianchini JAMA Network Michail ignatiadis Heather McArthur, MD, MPH, FASCO Renato Azambuja De lima e Otto Metzger #Cancer #BCSM #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes. Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:

Now out in Journal of Clinical Oncology the results of our global collaboration🌎 led by Matteo Lambertini, MD PhD showing different clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, and the impact of timing of genetic testing on prognosis - a thread👇🏻🧵 OncoAlert ascopubs.org/doi/10.1200/JC…

Press release from AstraZeneca on SERENA-6 phase 3 trial Camizestrant in combination with a CDK4/6i ⬆️ PFS in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation OncoAlert astrazeneca.com/media-centre/p…

Don't miss this recent JAMA pub on Adjuvant #Atezolizumab for Early #TripleNegativeBreastCancer, results from the ALEXANDRA/IMpassion030 Randomized Clinical Trial. 🔓pubmed.ncbi.nlm.nih.gov/39883436/ ✍️Michail ignatiadis Otto Metzger Heather McArthur, MD, MPH, FASCO Evandro de Azambuja, MD, PhD Gustavo Werutsky

🎯Glad to share our npj Journals Breast Cancer publication on ML-based spatial characterization of #TumorMicroenvironment in early #breastcancer in the EORTC Breast Cancer Group 10994/BIG 1-00 trial shorturl.at/nwYU6 Thanks to all collaborators! EORTC OncoAlert Michail ignatiadis Theodoros Foukakis

The 19th St. Gallen Conference took place this week in Vienna. Nearly 80 expert panelists voted on key debated topics in breast oncology, selected by Harold J. Burstein, MD, PhD, FASCO & G Curigliano MD PhD. Here’s 10 key results from the #SGBCC2025 consensus voting, divided by topic/breast cancer subtype.

Investigator-initiated study sponsored by Institut Jules Bordet Instituut and chaired by Alex De Caluwe and Laurence Buisseret. Primary endpoint results presented at #ESMO24 oncologypro.esmo.org/meeting-resour…

As expected, DB-09 showed significant improvement in PFS with T-DXd in 1️⃣st line in combination with pertuzumab, thus likely representing a practice-changing study for HER2+ #breastcancer Looking forward to seeing the data that will be presented soon🔜 OncoAlert

A surge in dual-payload conjugates 🎯 💣 💣 List of dual-payload ADCs to be presented at #AACR25:

T-DXd wins it all ✈️ This press release of DB-11 from industry announces significant ⬆️ in pCR with neoadjuvant T-DXd followed by THP in high-risk HER2+ #breastcancer Looking forward to the data 🔜 OncoAlert

Part of the Institut Jules Bordet Instituut breast cancer team at #ESMOBreast25 ✨ Evandro de Azambuja, MD, PhD Christos Sotiriou Michail ignatiadis @andreagombos

At #ASCO25 , Michail ignatiadis presented the study design of TREAT ctDNA, an academic randomized trial investigating ctDNA dynamics and the novel oral SERD elacestrant in HR+/HER2- early breast cancer clinicaltrials.gov/study/NCT05512… Institut Jules Bordet Instituut EORTC

🧬 #ASCO2025 Plenary Breast In-depth! Prof Michail ignatiadis & Dr Elisa Agostinetto on SERENA-6: 🔹 ctDNA-detected ESR1 mutations 🔹 Early switch to camizestrant improves PFS 🔹 Trial confirms value of molecular monitoring 🎥 Watch now bit.ly/4mLvOXR #MediMix

👉 Access the core content of the Metastatic Breast Cancer Living Guideline in a user-friendly format ready for you to use in your own presentations. 🔗 ow.ly/Ax0y50WcSQR